Oncology leaders from Alliance Cancer Specialists, American Oncology Network, CHI St. Vincent, Memorial Sloan Kettering ...

As the number of cell and gene therapies expands, it's increasingly important for long-term patient data, explained Fran ...

At Asembia’s AXS25 Summit, industry experts explored how pharmacy is evolving to meet rising patient expectations and ...

Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported ...

Jon Giles, MD, speaks to the power of personalized medicine and multidisciplinary care to enhance treatment for patients with ...

Liver transplantation is the sole curative option for HCC, but new therapies prompt reconsideration of transplant timing and ...

Efforts to more precisely select appropriate therapy for individual patients with rheumatoid arthritis have not yet yielded a ...

Early actions by the new administration signal major changes in health policy, taxes, and pharmaceutical pricing.

Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with ...

Evaluating the impact of the Inflation Reduction Act (IRA) will require real-time data and effective therapy metrics, ...

Jason Hawkes, MD, MS, provided an in-depth look at the potential role of dupilumab (Dupixent; Sanofi and Regeneron ...

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...